uniQure (NASDAQ:QURE) Director Sells $196,729.60 in Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 7,552 shares of uniQure stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $26.05, for a total value of $196,729.60. Following the sale, the director directly owned 27,435 shares of the company’s stock, valued at approximately $714,681.75. This trade represents a 21.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Thursday, June 11th, Robert Gut sold 2,726 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total value of $73,765.56.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $27.57 on Monday. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $22.52 and a two-hundred day simple moving average of $21.76. The firm has a market cap of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC purchased a new position in uniQure during the 4th quarter worth $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. IFP Advisors Inc purchased a new position in uniQure during the 4th quarter worth $48,000. Smartleaf Asset Management LLC purchased a new position in uniQure during the 4th quarter worth $48,000. Finally, CIBC Private Wealth Group LLC purchased a new position in uniQure during the 3rd quarter worth $50,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Analyst Ratings Changes

A number of research analysts have recently issued reports on QURE shares. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Wolfe Research started coverage on uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Stifel Nicolaus set a $28.00 price target on uniQure in a report on Tuesday, May 5th. Finally, Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $15.00 to $60.00 in a report on Monday, March 9th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and an average price target of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.